Literature DB >> 17515506

The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium.

Andrew C Hoover1, William C Spanos, George F Harris, Mary E Anderson, Aloysius J Klingelhutz, John H Lee.   

Abstract

OBJECTIVE: To provide a manipulatable system to study the mechanism of human papillomavirus 16 (HPV16) E6-related transformation of an epithelial cell type affected by HPV16 in humans.
DESIGN: Biochemical and physiological studies of mouse tonsil epithelial cells (MTECs) transformed with HPV16 oncogenes plus H-ras in vitro and in vivo.
SETTING: Basic research laboratory. PARTICIPANTS: C57BL/6 mice.
INTERVENTIONS: Transduction of the HPV16 oncogenes E6 and E7 in retroviral vectors into MTECs with isolation of multiple individual clones that expressed E6, E7, or both alone or in conjunction with H-ras. MAIN OUTCOME MEASURES: Growth in culture, anchorage-independent growth, and growth in immune competent, syngeneic mice.
RESULTS: The MTECs that expressed E6 degraded p53 by a mechanism that is inhibited by proteasomal blockade. Although normal MTECs senesced after 20 population doublings, E6 alone or in combination with E7 was sufficient to immortalize MTECs beyond 25 population doublings, lower their population-doubling time, and permit anchorage-independent growth. However, only MTECs that express E6 plus H-ras or E6/E7 plus H-ras formed invasive tumors in immune competent, syngeneic mice at orthotopic intraoral and subdermal sites.
CONCLUSIONS: We found that HPV16 E6 and E7 alone are not sufficient for invasive growth. However, the synergistic activity of H-ras and E6 was sufficient to result in invasive growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515506      PMCID: PMC2917346          DOI: 10.1001/archotol.133.5.495

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  36 in total

1.  Species- and cell type-specific requirements for cellular transformation.

Authors:  Annapoorni Rangarajan; Sue J Hong; Annie Gifford; Robert A Weinberg
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

2.  Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro.

Authors:  S I Shin; V H Freedman; R Risser; R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

Review 3.  Occurrence of leukaemia following gene therapy of X-linked SCID.

Authors:  Donald B Kohn; Michel Sadelain; Joseph C Glorioso
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

4.  The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells.

Authors:  C L Halbert; G W Demers; D A Galloway
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors.

Authors:  Karin Schreiber; Ronald E Cannon; Theodore Karrison; Gabriele Beck-Engeser; Dezheng Huo; Raymond W Tennant; Heather Jensen; W Martin Kast; Thomas Krausz; Stephen C Meredith; Lieping Chen; Hans Schreiber
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

6.  Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.

Authors:  Matthew A Ginos; Grier P Page; Bryan S Michalowicz; Ketan J Patel; Sonja E Volker; Stefan E Pambuccian; Frank G Ondrey; George L Adams; Patrick M Gaffney
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

7.  The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo.

Authors:  Marie L Nguyen; Minh M Nguyen; Denis Lee; Anne E Griep; Paul F Lambert
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells.

Authors:  A Storey; L Banks
Journal:  Oncogene       Date:  1993-04       Impact factor: 9.867

9.  Immortalization phenotype dissociated from the preneoplastic phenotype in mouse mammary epithelial outgrowths in vivo.

Authors:  D Medina; F S Kittrell
Journal:  Carcinogenesis       Date:  1993-01       Impact factor: 4.944

10.  HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.

Authors:  P Hawley-Nelson; K H Vousden; N L Hubbert; D R Lowy; J T Schiller
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  39 in total

1.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

2.  Sickness behavior induced by cisplatin chemotherapy and radiotherapy in a murine head and neck cancer model is associated with altered mitochondrial gene expression.

Authors:  Elisabeth G Vichaya; Jessica M Molkentine; Daniel W Vermeer; Adam K Walker; Rebekah Feng; Gerard Holder; Katherine Luu; Ryan M Mason; Leo Saligan; Cobi J Heijnen; Annemieke Kavelaars; Kathy A Mason; John H Lee; Robert Dantzer
Journal:  Behav Brain Res       Date:  2015-10-22       Impact factor: 3.332

3.  HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

Authors:  Sayuri Miyauchi; P Dominick Sanders; Kripa Guram; Sangwoo S Kim; Francesca Paolini; Aldo Venuti; Ezra E W Cohen; J Silvio Gutkind; Joseph A Califano; Andrew B Sharabi
Journal:  Cancer Res       Date:  2019-12-17       Impact factor: 12.701

4.  Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.

Authors:  Daniel W Vermeer; William C Spanos; Paola D Vermeer; Annie M Bruns; Kimberly M Lee; John H Lee
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

5.  Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.

Authors:  Dayson Moreira; Sagus Sampath; Haejung Won; Seok Voon White; Yu-Lin Su; Marice Alcantara; Chongkai Wang; Peter Lee; Ellie Maghami; Erminia Massarelli; Marcin Kortylewski
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

6.  Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers.

Authors:  Stephanie Dorta-Estremera; Renee L Chin; Gloria Sierra; Courtney Nicholas; Ananta V Yanamandra; Sita M K Nookala; Guojun Yang; Shail Singh; Michael A Curran; K Jagannadha Sastry
Journal:  Cancer Res       Date:  2018-07-27       Impact factor: 12.701

7.  Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells.

Authors:  Francoise A Gourronc; William M Rockey; William H Thiel; Paloma H Giangrande; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-09-08       Impact factor: 3.616

8.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

9.  The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.

Authors:  William C Spanos; Andrew Hoover; George F Harris; Shu Wu; Guinevere L Strand; Mary E Anderson; Aloysius J Klingelhutz; Wiljan Hendriks; Aaron D Bossler; John H Lee
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

10.  Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.

Authors:  A C Hoover; G L Strand; P N Nowicki; M E Anderson; P D Vermeer; A J Klingelhutz; A D Bossler; J V Pottala; W J A J Hendriks; J H Lee
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.